The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- Depression
- 62
Filter Results (13)
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Assessment of Psilocybin Therapy for Treatment of Depression in Parkinson’s Disease
Study Rationale: Depression is of the most common and disabling symptoms of Parkinson’s disease (PD), and it is linked to poor quality of life and faster disease progression. Unfortunately, we lack...
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Engaging the LGBTQIA+ Community, Caregivers and Care Providers in Research on Living with Parkinson’s Disease
Study Rationale: Four million LGBTQIA+ adults age 50 and above live in the United States. We know very little about the needs of those in the LGBTQIA+ community who are living with Parkinson’s disease...
-
Therapeutic Pipeline Program, 2021Using Ketamine to Treat Depression in Parkinson’s Disease
Study Rationale:
Depression affects around half of people with Parkinson’s disease (PD). However, existing antidepressants are not effective in treating these symptoms in PD and new treatments are... -
Research Grant, 2020Identification of Therapeutic Circuits to Address Anxiety and Depression Symptoms in Parkinson’s Disease
Study Rationale: Parkinson’s disease patients often experience depression and anxiety. Addressing these non-motor symptoms has not been the focus of Parkinson’s disease research though psychiatric...
-
Therapeutic Pipeline Program, 2015Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach
Study Rationale:
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)... -
Repositioning Drugs for PD, 2012Amitriptyline as a Dopamine Neuroprotective Therapy
Objective/Rationale:
The project proposes to repurpose the tricyclic antidepressant medication, amitriptyline (AMI), as a disease-modifying therapy for Parkinson’s disease (PD). AMI is an FDA-approved...

Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.